VTv Therapeutics (NASDAQ:VTVT) has risen 8.8% postmarket after it says it will present at this week's Alzheimer's Association International Conference.
The oral presentation will cover data from its phase 3 STEADFAST study and the preceding phase 2B study of azeliragon to "further support the biological hypothesis for the potential beneficial effects of azeliragon on the ADAS-cog and CDR-sb in patients with mild Alzheimer’s disease and type 2 diabetes."
Azeliragon is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts (RAGE). https://seekingalpha.com/news/3477913-vtv-therapeutics-present-alzheimers-conference-shares-plus-8_8-percent
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.